AGTX Agentix Corp.
Biological Products, (No Diagnostic Substances) · OTC · SEC CIK 1603345 · Fiscal year ends 03/31
Financial factors as of 2026-09-30 (2027Q2), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY44.4%
TTM EPS YoY0.0%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE—
ROA-10,542.6%
ROIC (approx.)—
Asset turnover—
Leverage & solvency
Liabilities / assets290,269.6%
Debt / equity—
Current ratio0.00x
Interest coverage-3.57x
Cash quality & payout
Operating cash flow / net income0.06x
Accruals ratio-9,875.5%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20262026-03-31 | FY20252025-03-31 | FY20242024-03-31 | FY20232023-03-31 | FY20222022-03-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | — | — | — | $0 | $1,240 |
| Cost of revenue | — | — | — | $0 | $561 |
| Gross profit | — | — | — | $0 | $679 |
| R&D expense | $125,079 | $180,987 | $175,268 | $711,506 | $279,912 |
| SG&A expense | $68,072 | $69,898 | $346,543 | $140,012 | $165,355 |
| Operating income | -$445,187 | -$513,251 | -$744,810 | -$1.37M | -$2.63M |
| Interest expense | $80,106 | $42,669 | $21,034 | $1,643 | $0 |
| Pretax income | -$485,636 | -$567,048 | -$585,154 | -$1.37M | -$2.63M |
| Income tax | $0 | $0 | $0 | $0 | $0 |
| Net income | -$485,636 | -$567,048 | -$585,154 | -$1.37M | -$2.63M |
| EPS (diluted) | -0.01 | -0.01 | -0.01 | — | — |
| Weighted avg. shares (diluted) | 40.07M | 40.07M | 40.07M | — | — |
| Balance sheet | |||||
| Cash & equivalents | $771 | $4,477 | $6,535 | $12,369 | $145 |
| Inventory | — | — | — | — | $0 |
| Current assets | $771 | $100,274 | $106,372 | $261,392 | $15,978 |
| Total assets | $771 | $100,274 | $106,372 | $261,392 | $15,978 |
| Current liabilities | $3.60M | $3.20M | $2.67M | $2.51M | $1.09M |
| Total liabilities | $3.60M | $3.20M | $2.67M | $2.51M | $1.09M |
| Shareholders' equity | -$3.60M | -$3.10M | -$2.56M | -$2.25M | -$1.08M |
| Shares outstanding | 40.07M | 40.07M | 40.07M | 40.07M | 38.92M |
| Cash flow statement | |||||
| Operating cash flow | -$108,529 | -$125,078 | -$110,429 | -$88,541 | -$25,204 |
| Investing cash flow | $0 | $0 | $0 | $0 | $0 |
| Financing cash flow | $110,450 | $100,000 | $93,000 | $100,000 | $0 |
Free plan shows the latest 5 periods; Pro shows all 12 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.